{"id":115902,"date":"2026-06-25T05:30:12","date_gmt":"2026-06-25T05:30:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/115902\/"},"modified":"2026-06-25T05:30:12","modified_gmt":"2026-06-25T05:30:12","slug":"novo-nordisk-finds-medicare-patients-prefer-glp-1-pill-over-shot-for-weight-loss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/115902\/","title":{"rendered":"Novo Nordisk Finds Medicare Patients Prefer GLP-1 Pill Over Shot for Weight Loss"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVOB:DC\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novo Nordisk A\/S<\/a> said its market research shows twice as many US Medicare recipients would rather take a weight-loss pill over a shot, a preference the Danish drugmaker will try to use to grab market share from its rival <a href=\"https:\/\/www.bloomberg.com\/quote\/LLY:US\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Eli Lilly &amp; Co.<\/a> <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">About three-quarters of Medicare recipients had a preference regarding whether to take a daily pill or weekly shot, US chief Jamey Millar said in an interview with Bloomberg TV. Of those, twice as many preferred a pill, he said.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S said its market research shows twice as many US Medicare recipients would rather take a&hellip;\n","protected":false},"author":2,"featured_media":115903,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[691,16167,71,4007,1585,39896,730,4239,272,13578,21306,3851],"class_list":["post-115902","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drugs","tag-eli-lilly-co","tag-europe","tag-finance","tag-government","tag-industrials","tag-industries","tag-jamey-millar","tag-novo-nordisk","tag-novo-nordisk-a-s-b","tag-pharmaceutical","tag-retail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116809106879088102","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/115902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=115902"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/115902\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/115903"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=115902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=115902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=115902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}